lockPublications / ReportMalaria Futures for Central Africa
The MalaFA CA (Malaria Futures for Central Africa supplementary report) is the latest extension of the Malaria Futures for Africa (MalaFA) study, commissioned by Novartis, which has already conducted similar research across 15 countries in Africa. The new supplementary report involved interviews with politicians, senior civil servants, malaria program directors, researchers and NGOs in Cameroon, Democratic Republic of the Congo (DRC), Republic of Congo, and Rwanda. All four are countries that have a significant malaria burden and differing policies in place to fight the disease. Study co-chairs are Dr Richard Kamwi, Ambassador, Elimination 8 (E8), and Professor Bob Snow, of the KEMRI-Wellcome Trust programme, Kenya and University of Oxford, United Kingdom.
lockPublications / ReportNovartis in Society US Report 2019
Our stakeholders have important questions about our business practices in the United States, including our approach to price adjustments, patient assistance, investment in research and development, and marketing. The Novartis in Society US report aims to help answer those questions.
lockPublications / ReportNovartis Annual Report 2019
Our Annual Report 2019 provides a comprehensive overview of Novartis, including our corporate governance, compensation practices, and operating and financial results.
lockPublications / ReportNovartis Annual Report 2020
This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also discloses our operating and financial results, accompanied by audited annual financial statements.
lockPublications / ReportNovartis in Society ESG Report 2020
The Novartis in Society ESG Report details progress on environmental, social and governance topics and demonstrates the company’s commitment in global health and corporate responsibility.
lockPublications / ReportNovartis in Society US Report 2020
Novartis is working on multiple fronts in the United States to build trust and expand access to healthcare in challenging times. The Novartis in Society US report details some of our initiatives in corporate responsibility, science & innovation, value & pricing, and responsible business practices.